Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neo-Ts
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Subcutaneous, Intradermal
01
Overview
Neo-Ts refers to neoantigen-specific CD8+ T cells, a type of adoptive T cell therapy (ACT) developed to target individual patient's unique tumor mutations. This cell therapy aims to increase treatment efficacy in cancers that are refractory to standard therapies. In a Phase I clinical trial (NCT02959905), Neo-Ts were generated from patients with locally advanced or metastatic melanoma or colon cancers. The therapy was evaluated for safety and objective response rate, showing promising results with or without lymphodepletion. The median progression-free survival was 7.1 months, and the median overall survival was 16.8 months, with an objective response rate of 33.3%. Neoantigen-specific T cell receptors were observed to expand and persist after treatment in responding patients.
- Other names
- neoantigen-specific CD8+ T cells
02
Targets
pMHC-I (Neoantigen peptide–Major Histocompatibility Complex class I)
Beyond the preview
Go deeper on Neo-Ts.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neo-Ts.